Gilead Sciences (GILD) 87.00 $GILD
The Medicines Patent Pool Signs a Record Seven New Sub-Licences to Speed the Availability of Generic HIV Medicines to Developing Countries
PR Newswire - 1 hr 26 mins ago
MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014
Business Wire - Wed Jul 16, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2014 financial results will be released on Wednesday, July 23, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the second quarter 2014 and provide a general business update. The conference call will be accessible via the internet from the company's website.
Gilead Stock Earnings: What to Watch
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Jul 16, 4:00PM CDT
Gilead Sciences has had a great year so far, with Sovaldi (its hepatitis c cure) turning in an incredible $2.3 billion in sales in its first full quarter on the market. Sovaldi's performance has helped fuel Gilead's 18% price gain year-to-date. ...
Midday Glance: Biotechnology companies
AP - Wed Jul 16, 1:54PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Keep Calm and Carry On, J&J
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jul 16, 1:00PM CDT
If bellwether Johnson & Johnson is any indication, fasten your seatbelts. We're in for a volatile earnings season. The company delivered strong quarterly results, led by unexpectedly stellar sales of its new hepatitis C drug Olysio. But the...
Early Glance: Biotechnology companies
AP - Wed Jul 16, 10:11AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Jim Cramer's Stop Trading: Speculation Isn't Bad
at The Street - Wed Jul 16, 10:09AM CDT
TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, argued that investors have a right to speculate, despite Fed Chair Janet Yellen's thoughts on valuation.
Stock Market News for July 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 9:10AM CDT
Benchmarks finished on a mixed note on Tuesday after a Fed monetary policy report sparked concerns about “substantially stretched valuations” in Internet and bio-tech stocks
Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 16, 8:49AM CDT
Focus last week remained on AbbVie's (ABBV) attempts to acquire Shire (SHPG) - the company came back with a revised offer which could very well be accepted by Shire.
J&J Earnings Beat Estimates, But Guidance Mixed
at Investor's Business Daily - Tue Jul 15, 2:15PM CDT
Johnson & Johnson (JNJ) on Tuesday delivered strong quarterly results, led by its hepatitis C drug Olysio. But J&J shares slid nearly 2% in afternoon trading on the stock market today, as the medical giant does not expect the growth rate to continue....
2 Reasons to Watch Bristol-Myers Squibb Co
Cory Renauer, The Motley Fool - Motley Fool - Tue Jul 15, 1:00PM CDT
Like many drug majors Bristol-Myers Squibb will face heavy losses to generic competition in the years ahead. In an effort to maximize efficiency the company has narrowed its focus to areas with unmet need rather than making incremental...
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
Economic News Today: Yellen Says Some Stock Valuations 'Stretched'
at Investor's Business Daily - Tue Jul 15, 10:30AM CDT
Federal Reserve Chairwoman Janet Yellen told the Senate Banking Committee that the "equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched." That sent U.S. stock indexes lower in morning trading. But...
1 Hidden Blockbuster Lurking in Merck's Pipeline?
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 14, 4:00PM CDT
Merck already markets Isentress, one of the most widely used medications for the treatment of HIV, but it has another drug in its pipeline that may also become a blockbuster someday, too. Doravirine, also known as MK-1439, is currently in...
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.26%
Comtex SmarTrend(R) - Mon Jul 14, 3:47PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $88.84 to a high of $90.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $89.98 on volume of 10.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.26% Yesterday
Comtex SmarTrend(R) - Mon Jul 14, 3:46PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $88.84 to a high of $90.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $89.98 on volume of 10.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 10:30AM CDT
Two members of the U.S. Senate Finance Committee issued a letter to Gilead asking it to justify the high price of Sovaldi.
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $89.72
Comtex SmarTrend(R) - Mon Jul 14, 9:04AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $88.99 today and have reached the first resistance level of $89.72. Should the shares continue to rise, the resistance pivots of $90.72 and $92.45 will be of interest.
The Medicines Patent Pool Signs a Record Seven New Sub-Licences to Speed the Availability of Generic HIV Medicines to Developing Countries
PR Newswire - 1 hr 26 mins ago
MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014
Business Wire - Wed Jul 16, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2014 financial results will be released on Wednesday, July 23, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the second quarter 2014 and provide a general business update. The conference call will be accessible via the internet from the company's website.
Gilead Stock Earnings: What to Watch
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Jul 16, 4:00PM CDT
Gilead Sciences has had a great year so far, with Sovaldi (its hepatitis c cure) turning in an incredible $2.3 billion in sales in its first full quarter on the market. Sovaldi's performance has helped fuel Gilead's 18% price gain year-to-date. ...
Midday Glance: Biotechnology companies
AP - Wed Jul 16, 1:54PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Keep Calm and Carry On, J&J
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jul 16, 1:00PM CDT
If bellwether Johnson & Johnson is any indication, fasten your seatbelts. We're in for a volatile earnings season. The company delivered strong quarterly results, led by unexpectedly stellar sales of its new hepatitis C drug Olysio. But the...
Early Glance: Biotechnology companies
AP - Wed Jul 16, 10:11AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Jim Cramer's Stop Trading: Speculation Isn't Bad
at The Street - Wed Jul 16, 10:09AM CDT
TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, argued that investors have a right to speculate, despite Fed Chair Janet Yellen's thoughts on valuation.
Stock Market News for July 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 9:10AM CDT
Benchmarks finished on a mixed note on Tuesday after a Fed monetary policy report sparked concerns about “substantially stretched valuations” in Internet and bio-tech stocks
Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 16, 8:49AM CDT
Focus last week remained on AbbVie's (ABBV) attempts to acquire Shire (SHPG) - the company came back with a revised offer which could very well be accepted by Shire.
J&J Earnings Beat Estimates, But Guidance Mixed
at Investor's Business Daily - Tue Jul 15, 2:15PM CDT
Johnson & Johnson (JNJ) on Tuesday delivered strong quarterly results, led by its hepatitis C drug Olysio. But J&J shares slid nearly 2% in afternoon trading on the stock market today, as the medical giant does not expect the growth rate to continue....
2 Reasons to Watch Bristol-Myers Squibb Co
Cory Renauer, The Motley Fool - Motley Fool - Tue Jul 15, 1:00PM CDT
Like many drug majors Bristol-Myers Squibb will face heavy losses to generic competition in the years ahead. In an effort to maximize efficiency the company has narrowed its focus to areas with unmet need rather than making incremental...
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
Economic News Today: Yellen Says Some Stock Valuations 'Stretched'
at Investor's Business Daily - Tue Jul 15, 10:30AM CDT
Federal Reserve Chairwoman Janet Yellen told the Senate Banking Committee that the "equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched." That sent U.S. stock indexes lower in morning trading. But...
1 Hidden Blockbuster Lurking in Merck's Pipeline?
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 14, 4:00PM CDT
Merck already markets Isentress, one of the most widely used medications for the treatment of HIV, but it has another drug in its pipeline that may also become a blockbuster someday, too. Doravirine, also known as MK-1439, is currently in...
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.26%
Comtex SmarTrend(R) - Mon Jul 14, 3:47PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $88.84 to a high of $90.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $89.98 on volume of 10.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.26% Yesterday
Comtex SmarTrend(R) - Mon Jul 14, 3:46PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $88.84 to a high of $90.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $89.98 on volume of 10.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 10:30AM CDT
Two members of the U.S. Senate Finance Committee issued a letter to Gilead asking it to justify the high price of Sovaldi.
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $89.72
Comtex SmarTrend(R) - Mon Jul 14, 9:04AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $88.99 today and have reached the first resistance level of $89.72. Should the shares continue to rise, the resistance pivots of $90.72 and $92.45 will be of interest.
